Merck’s experimental blood thinner Vorapaxar shows promise in significantly reducing the risk of dying from heart attack or stroke, but the associated risk of hemorrhage has some experts wondering if the drug will make it past United States drug regulators. Vorapaxar is an anti-platelet medicine that works differently that aspirin or the popular warfarin (Coumadin). It is in a new class of medications known as thrombin receptor antagonists, which work by stopping a process that normally allows the blood’s platelets to stick together and form clots. The medication is designed to prevent heart attacks and strokes and was tested in ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.